Skip to main content
Journal of Genetic Engineering and Biotechnology
Download PDF

Correction: Biosynthesis of a VLP-type nanocarrier specifc to cancer cells using the BEVS expression system for targeted drug delivery

Journal of Genetic Engineering and Biotechnology volume 21, Article number: 40 (2023) Cite this article

The Original Article was published on 16 February 2023

Correction: J Genet Eng Biotechnol 21, 20 (2023)

https://doi.org/10.1186/s43141-023-00479-9

Following publication of the original article [1], the author group has identified an error in Figs. 3, 4, and 6. The correct figures are given below.

Fig. 3
figure 1

SDS-PAGE results of the proteins extracted from the Sf9 cells infected by the recombinant baculoviruses encoding VP2. a The proteome of the cells infected with MOI of 1 (pfu/cell) and b the proteome of the cells infected with MOI of 10 (pfu/cell). Lane 1: The cell control, lanes 2 and 8: Molecular weight marker (Fermentas) and lanes 3–7: The protein samples taken at the harvest times of 24, 48, 72, 96, and 120 hpi, and the expected band (⁓64 kDa) corresponding to the recombinant expressed VP2

Full size image
Fig. 4
figure 2

a Quantitative analysis of the expressed recombinant VP2 as well as the total protein content in the flasks infected with MOI of 1 (pfu/cell) at the harvest times of 24, 48, 72, 96, and 120 hpi. b Quantitative analysis of the expressed recombinant VP2 as well as the total protein content in the flasks infected with MOI of 10 (pfu/cell) at the mentioned times. c Comparison of quantitative analysis of the recombinant VP2 expression rate in the flasks infected with two MOIs of 1 and 10 (pfu/cell) at the mentioned time point. The results showed that the optimal expression of VP2 is related to the flask inoculated with MOI of 10 (pfu/cell) at the harvest time of 72 hpi

Full size image
Fig. 6
figure 3

Evaluation results of the quality and structural integrity of the purifed VLPs by TEM, HA, and DLS. a The purifed VLPs imaged by TEM with a magnifcation of 120,000 X. b HA test in a 96-well U shaped plate. Row 1: The results indicate the strong hemagglutination in the dilutions of 1, 2, 4, 8, and 16 and weakening of hemagglutination in the dilutions of 32, 64, and 128, and fnally, the negative hemagglutination in the dilutions of 256, 512, and 1024. In total, the hemagglutination property of the produced VLPs indicates the quality and structural integrity of these nanoparticles. Row 2: The negative control of HA containing PBS and RBC without the presence of the VLP. c Calculation of the size distribution of CPV-VLP nanoparticles by DLS technique. This analysis shows that 68.8% of the formed nanoparticles had a size of about 25.12 nm and 31.2% of these nanoparticles had a size of about 184.4 nm

Full size image

The original article [1] has been corrected.

Reference

  1. Hashemzadeh MS, Gharari N (2023) Biosynthesis of a VLP-type nanocarrier specific to cancer cells using the BEVS expression system for targeted drug delivery. J Genet Eng Biotechnol 21:20. https://doi.org/10.1186/s43141-023-00479-9

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nanobiotechnology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran

    Mohammad Sadegh Hashemzadeh

  2. Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy

    Nariman Gharari

Authors
  1. Mohammad Sadegh Hashemzadeh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nariman Gharari
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mohammad Sadegh Hashemzadeh.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hashemzadeh, M.S., Gharari, N. Correction: Biosynthesis of a VLP-type nanocarrier specifc to cancer cells using the BEVS expression system for targeted drug delivery. J Genet Eng Biotechnol 21, 40 (2023). https://doi.org/10.1186/s43141-023-00485-x

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/s43141-023-00485-x